Pfizer recently made an announcement confirming that its experimental oral inhibitor, Janus kinase 3 (JAK3) or PF-06651600, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Apparently, the inhibitor is being developed for treating patients suffering from alopecia areata, …
The National Health Service (NHS), the national healthcare system of England, has reportedly made plans to treat young people and children stricken with cancer with a costly yet revolutionary cancer drug, which has enormous potential to transform the way this disease is treated. According to …
Software behemoth Microsoft is reportedly developing technologically advanced spectacles that incessantly monitor blood pressure all day, in a bid to reduce the risk of strokes and heart attacks. According to sources familiar with the development, these spectacles are presumed to have in-built hidden sensors at …
Researchers at the University of Colorado Boulder have reportedly developed an unconventional genetic disruption strategy that successfully stymies the growth of antibiotic-resistant bacteria, giving scientists an edge over deadly superbugs. According to data from the Centers for Disease Control, these multiple drug resistant pathogens — …
Renowned for-profit healthcare facility provider, HCA Healthcare, based out of Nashville, has seemingly made it to the headlines for having announced its decision to acquire Mission Health. As per trusted sources, the North Carolina based health system, Mission Health, has signed a definitive agreement with …
Renowned New York-based pharma magnate Pfizer Inc., has reportedly axed two trials of its Domagrozuma antibody. As per sources, the candidate development has been halted on the grounds of its disappointing failure to meet the required efficacy targets. For the uninitiated, the anti-myostatin antibody is …
Alibaba, the Chinese multinational giant, has recently launched an online medical consultation and 24-hour medicine delivery service on its Taobao marketplace platform. As per sources familiar with the matter, users can now seek urgent medical attention or medications whenever required, and over-the counter medicines ordered …
AstraZeneca along with its global biologics research and development business, MedImmune, has reportedly announced that the phase III trial for anifrolumab has failed to meet its primary goal. As per trusted sources, the complete evaluation of the data is likely to be conducted after the …
Voluntis, a medical intelligence firm that develops advanced digital therapeutics to enhance medications and medical devices, has reportedly announced to extend its collaboration with AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, in a bid to advance oncology treatment technology. The new agreement states that the …
